amantadine and Aging
amantadine has been researched along with Aging in 11 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| " Drugs used to treat PD, such as levodopa, offer symptomatic relief but often have neuropsychiatric adverse effects, most prominently psychosis and delirium." | 4.79 | Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. ( Camicioli, R; Ganzini, L; Young, BK, 1997) |
| "Epidemic influenza occurred only in the two groups of conscripts: the incidence of serologically verified influenza was 66% and 83% in the groups that received placebo and 43% and 51% in the groups that received amantadine, giving protection rates of 36% (P = 0." | 2.65 | Evaluation of amantadine in the prophylaxis of influenza A (H1N1) virus infection: a controlled field trial among young adults and high-risk patients. ( Hellström, PE; Penttinen, K; Pettersson, RF; Pyhälä, R; Tokola, O; Vartio, T; Visakorpi, R, 1980) |
| "The development of pneumonia is a life-threatening event in a nursing home resident." | 2.37 | Pneumonia in the elderly: a nursing home perspective. ( Gleckman, RA; Roth, RM, 1985) |
| "Amantadine was administered to 676 patients with influenza A (A+Am group)." | 1.33 | Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. ( Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Kawashima, T; Maeda, T; Miyachi, K; Satoh, I; Shigematsu, T, 2005) |
| "Vaccination is more difficult for influenza than for pneumococcal pneumonia." | 1.27 | Vaccinating the elderly: recommendations and rationale. ( Alvarez, S; Berk, SL, 1986) |
Research
Studies (11)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (54.55) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Kasná, A | 1 |
| Turánek, J | 1 |
| Vacek, A | 1 |
| Záluská, D | 1 |
| Knötigová, P | 1 |
| Masek, K | 1 |
| Kawai, N | 1 |
| Ikematsu, H | 1 |
| Iwaki, N | 1 |
| Satoh, I | 1 |
| Kawashima, T | 1 |
| Maeda, T | 1 |
| Miyachi, K | 1 |
| Hirotsu, N | 1 |
| Shigematsu, T | 1 |
| Kashiwagi, S | 1 |
| Pettersson, RF | 1 |
| Hellström, PE | 1 |
| Penttinen, K | 1 |
| Pyhälä, R | 1 |
| Tokola, O | 1 |
| Vartio, T | 1 |
| Visakorpi, R | 1 |
| Gaudry, SE | 1 |
| Sitar, DS | 1 |
| Smyth, DD | 1 |
| McKenzie, JK | 1 |
| Aoki, FY | 1 |
| Young, BK | 1 |
| Camicioli, R | 1 |
| Ganzini, L | 1 |
| Vamvakidès, A | 1 |
| Greer, M | 1 |
| Mostow, SR | 1 |
| Roth, RM | 1 |
| Gleckman, RA | 1 |
| Berk, SL | 1 |
| Alvarez, S | 1 |
| Bunn, PA | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Urinary Excretion of Acetylamantadine by Cancer Patients[NCT02277938] | 120 participants (Anticipated) | Observational | 2013-08-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reviews
2 reviews available for amantadine and Aging
| Article | Year |
|---|---|
Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.
Topics: Aging; Akathisia, Drug-Induced; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Cholinergic | 1997 |
Pneumonia in the elderly: a nursing home perspective.
Topics: Aged; Aging; Amantadine; Anti-Bacterial Agents; Bacterial Vaccines; Diagnosis, Differential; Humans; | 1985 |
Trials
2 trials available for amantadine and Aging
| Article | Year |
|---|---|
Evaluation of amantadine in the prophylaxis of influenza A (H1N1) virus infection: a controlled field trial among young adults and high-risk patients.
Topics: Adult; Aged; Aging; Amantadine; Antibodies, Viral; Clinical Trials as Topic; Disease Outbreaks; Doub | 1980 |
Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine.
Topics: Adult; Aged; Aging; Amantadine; Analysis of Variance; Drug Interactions; Female; Humans; Kidney; Mal | 1993 |
Other Studies
7 other studies available for amantadine and Aging
| Article | Year |
|---|---|
Restoration of femoral GM-CFC progenitors in sublethally irradiated mice of various ages treated with liposomal adamantylamide dipeptide.
Topics: Aging; Amantadine; Animals; Cells, Cultured; Dipeptides; Dose-Response Relationship, Radiation; Fema | 2004 |
Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season.
Topics: Acetamides; Adolescent; Adult; Aged; Aging; Amantadine; Antiviral Agents; Child; Child, Preschool; F | 2005 |
[Effect of amantadine or 3-cyclopentyl adamantanamine on the immobility of adult or aged mice, in the forced swim test].
Topics: Adamantane; Aging; Amantadine; Animals; Antiparkinson Agents; Brain; Imipramine; Male; Mice; Mice, I | 2000 |
Recent developments in the treatment of Parkinson's disease.
Topics: Aged; Aging; Amantadine; Diagnosis, Differential; Drug Administration Schedule; Dyskinesia, Drug-Ind | 1985 |
Steven R. Mostow, MD: why vaccinate the elderly?. Interview by Richard L. Peck.
Topics: Aged; Aging; Amantadine; Humans; Influenza Vaccines; Influenza, Human | 1987 |
Vaccinating the elderly: recommendations and rationale.
Topics: Aged; Aging; Amantadine; Creatinine; Female; Humans; Influenza Vaccines; Influenza, Human; Male; Mid | 1986 |
Pneumonia in the older patient.
Topics: Aged; Aging; Amantadine; Anti-Bacterial Agents; Cephalosporins; DNA Nucleotidyltransferases; Gentami | 1968 |